News & Blog

Coeliac Disease is a chronic immune disorder whereby the body’s own immune system mistakenly attacks healthy tissue when triggered by gluten ingestion.

A successful next generation sequencing assay using cell free DNA (cfDNA) relies heavily on the pre-analytical steps; sample collection, storage and cfDNA extraction.

Nonacus and the University of Birmingham have partnered to develop a non-invasive urine test for bladder cancer. The test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus.

Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma is being used to determine fetal RhD blood group antigen status so that RhD-negative pregnant women can avoid receiving antenatal anti-D if they are carrying a RhD-negative baby.

Government regulations, recently announced in the UK, now require Whole Genome Sequencing to be carried out as part of the minimum standards for COVID-19 tests for people arriving in England. In order to support SARS-CoV-2 testing laboratories, we have introduced a Whole Genome Sequencing service.

When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose- to develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn't easy. Find out why they went with 'Nonacus'.

This week Nonacus Ltd announced a partnership with Dante Labs and Cambridge Cancer Genomics which aims to build the most comprehensive and patient-centric tumour profiling service enabling improved cancer patient management, treatment and monitoring.

Nonacus was recently awarded an Innovate UK grant to validate novel, rapid surveillance testing for respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the SARS-CoV-2 genome and with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too.

Nonacus scientists, together with researchers at the University of Cambridge, are working on the development of a novel, non-invasive test for coeliac disease that works even if the patient is already on a gluten-free diet.